SCIG Hizentra denied as non-formulary by Aetna?

Aetna's specific coverage criteria for scig hizentra are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Hizentra as Non-Formulary

Aetna's formulary (Preferred Drug List) may place Hizentra on a non-preferred or excluded tier, or may designate a different immunoglobulin product — whether intravenous (IVIG) or another SCIG brand — as the preferred alternative. A non-formulary denial does not mean Hizentra is medically inappropriate; it means Aetna's default preference is a different product, and you must demonstrate why Hizentra specifically is necessary for this patient.

## Why This Denial Is Appealable

Formulary placement is not a clinical judgment. When a prescriber determines that a non-preferred product is medically necessary — due to tolerability, prior adverse reactions, clinical response, or patient-specific factors — plans are required to provide a meaningful exceptions process. A well-documented formulary exception or medical-necessity appeal can succeed.

## Federal Appeal Framework

• Formulary exception request: File this first — it is faster than a full appeal and directly addresses the formulary issue. Attach clinical justification showing why the preferred alternative is not appropriate for this patient.
• Internal appeal: If the exception is denied, escalate to a formal internal appeal. Aetna must review within standard timelines (30 days non-urgent, 72 hours expedited).
• External review (ACA §2719): After exhausting internal appeals, request IRO review within 4 months. The IRO evaluates whether the denial was consistent with generally accepted standards of care.

## Documentation to Gather

1. Formulary alternative history — records showing any trial of the preferred IVIG or SCIG product: dates, doses, clinical response, and reason for discontinuation or inadequacy. 2. Adverse reaction documentation — if the preferred alternative caused or is likely to cause adverse effects, include prescriber notes and any relevant clinical records. 3. Route and setting rationale — if the subcutaneous route is specifically required (e.g., poor venous access, infusion-site reactions to IVIG, home-administration safety), document this explicitly. 4. Prescriber attestation — a letter from the treating specialist explaining why Hizentra, and not the preferred formulary product, is medically necessary for this patient.

## Criteria-Mapping Strategy

Review Aetna's published formulary exception criteria alongside the FDA-approved prescribing label for Hizentra. For each exception criterion Aetna lists, provide a direct chart-based answer. Highlight any documented clinical difference between Hizentra and the preferred product that is relevant to this patient's safety or response. The goal is to show that substituting the preferred product would not provide equivalent clinical benefit.